Your browser is no longer supported. Please, upgrade your browser.
Settings
ARDX Ardelyx, Inc. daily Stock Chart
ARDX [NASD]
Ardelyx, Inc.
Index- P/E- EPS (ttm)-1.68 Insider Own1.10% Shs Outstand64.48M Perf Week-6.02%
Market Cap181.19M Forward P/E- EPS next Y-1.14 Insider Trans-5.02% Shs Float61.99M Perf Month-15.36%
Income-100.40M PEG- EPS next Q-0.38 Inst Own83.30% Short Float1.03% Perf Quarter8.08%
Sales0.30M P/S603.96 EPS this Y-19.70% Inst Trans-1.40% Short Ratio3.35 Perf Half Y-0.71%
Book/sh1.47 P/B1.91 EPS next Y21.90% ROA-51.20% Target Price10.75 Perf Year-27.95%
Cash/sh2.35 P/C1.20 EPS next 5Y30.00% ROE-78.40% 52W Range1.60 - 4.70 Perf YTD56.98%
Dividend- P/FCF- EPS past 5Y-33.60% ROI-55.10% 52W High-40.21% Beta1.98
Dividend %- Quick Ratio7.40 Sales past 5Y-38.20% Gross Margin99.30% 52W Low75.62% ATR0.19
Employees86 Current Ratio7.40 Sales Q/Q- Oper. Margin- RSI (14)38.91 Volatility7.27% 5.70%
OptionableYes Debt/Eq0.54 EPS Q/Q-16.80% Profit Margin- Rel Volume0.38 Prev Close2.73
ShortableYes LT Debt/Eq0.54 EarningsJun 05 AMC Payout- Avg Volume191.21K Price2.81
Recom1.20 SMA20-11.57% SMA50-13.41% SMA200-10.13% Volume72,131 Change2.93%
Apr-08-19Initiated Piper Jaffray Overweight $15
Aug-24-18Initiated Jefferies Buy $7
Mar-19-18Resumed Leerink Partners Outperform $13
Nov-29-17Reiterated Citigroup Buy $16 → $17
Nov-22-17Reiterated Ladenburg Thalmann Buy $19 → $16
Oct-17-17Resumed Leerink Partners Outperform
Mar-31-16Initiated Ladenburg Thalmann Buy
Mar-09-16Initiated Cantor Fitzgerald Buy $19
Mar-03-16Initiated Citigroup Buy
May-16-19 12:56PM  Why Ardelyx, Inc.'s (NASDAQ:ARDX) CEO Pay Matters To You Simply Wall St.
May-07-19 06:45PM  Ardelyx (ARDX) Reports Q1 Loss, Misses Revenue Estimates Zacks
05:34PM  Ardelyx: 1Q Earnings Snapshot Associated Press
04:02PM  Ardelyx Reports First Quarter 2019 Financial Results and Recent Business Highlights PR Newswire
10:30AM  Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy? Zacks
May-06-19 09:55AM  What's in the Cards for Axon Enterprise (AAXN) Earnings? Zacks
Apr-10-19 12:33PM  If You Had Bought Ardelyx (NASDAQ:ARDX) Stock Three Years Ago, You'd Be Sitting On A 57% Loss, Today Simply Wall St. +6.67%
Mar-19-19 05:38PM  East Bay company's drug may shrink dialysis patient 'pill burden.' But will it help them live longer? American City Business Journals
Mar-14-19 05:00PM  Ardelyx Appoints Renowned Nephrologist, Geoffrey A. Block, M.D., to Its Board of Directors PR Newswire
Mar-07-19 05:00PM  Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology PR Newswire +13.68%
Mar-06-19 04:05PM  Ardelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights PR Newswire -5.00%
Mar-01-19 02:54PM  An Examination Of Ardelyx, Inc. (NASDAQ:ARDX) Simply Wall St. +7.83%
Feb-21-19 08:00AM  Ardelyx to Participate in Leerink Partners 8th Annual Global Healthcare Conference PR Newswire
Feb-12-19 08:25AM  Factors of Influence in 2019, Key Indicators and Opportunity within Park Hotels & Resorts, Planet Fitness, Aevi Genomic Medicine, Ardelyx, AMERISAFE, and inTest New Research Emphasizes Economic Growth GlobeNewswire
Feb-07-19 06:30AM  Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan PR Newswire
Jan-18-19 09:20AM  Ardelyx, Inc. (NASDAQ:ARDX) Is Trading At A 28.78% Discount Simply Wall St.
Dec-18-18 02:50AM  Ardelyx Inc (ARDX): Are Hedge Funds Right About This Stock? Insider Monkey
Nov-26-18 02:26PM  What Type Of Shareholder Owns Ardelyx Incs (NASDAQ:ARDX)? Simply Wall St.
Nov-13-18 08:30AM  Ardelyx Announces FDA Acceptance of the Filing of its New Drug Application for Tenapanor for the Treatment of Patients with IBS-C PR Newswire -5.42%
Nov-07-18 06:12PM  Ardelyx: 3Q Earnings Snapshot Associated Press
04:05PM  Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights PR Newswire
Oct-26-18 01:01PM  Ardelyx Presents New Preclinical Data Demonstrating Synergy between Tenapanor and Sevelamer When Dosed in Combination for Elevated Serum Phosphorus PR Newswire -16.81%
Oct-16-18 07:50AM  Analysis: Positioning to Benefit within Ardelyx, AXT, TG Therapeutics, MarineMax, Oclaro, and BioCryst Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire +7.28%
Oct-08-18 08:01AM  Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting PR Newswire
Oct-04-18 06:30AM  Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders PR Newswire
Sep-18-18 08:19AM  How Does Investing In Ardelyx Inc (NASDAQ:ARDX) Impact Your Portfolio? Simply Wall St.
Sep-13-18 06:30AM  Ardelyx Submits New Drug Application for U.S. Marketing Authorization of Tenapanor for IBS-C to U.S. Food and Drug Administration PR Newswire
Aug-29-18 02:16PM  Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption PR Newswire
Aug-17-18 01:40PM  Edited Transcript of ARDX earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
08:20AM  Consolidated Research: 2018 Summary Expectations for PDF Solutions, MYOS RENS Technology, Aldeyra Therapeutics, The Ensign Group, Everi, and Ardelyx Fundamental Analysis, Key Performance Indications GlobeNewswire
Aug-07-18 04:51PM  Ardelyx: 2Q Earnings Snapshot Associated Press
04:01PM  Ardelyx Reports Second Quarter 2018 Financial Results and Recent Highlights PR Newswire
02:30PM  Ardelyx, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-18 06:30AM  Ardelyx Announces Date of Second Quarter 2018 Financial Results and Conference Call PR Newswire
Jun-26-18 07:10AM  Free Technical Reports on Array BioPharma and Three Additional Biotech Equities ACCESSWIRE
May-31-18 07:40AM  Consolidated Research: 2018 Summary Expectations for CorVel, Consol Energy, Ardelyx, Aevi Genomic Medicine, Proofpoint, and Brink's Fundamental Analysis, Key Performance Indications GlobeNewswire
May-29-18 06:30AM  Ardelyx to Present at the Jefferies 2018 Global Healthcare Conference PR Newswire
May-23-18 01:39PM  Why Ardelyx Inc. Is Down by Double Digits for a Second Day in a Row Motley Fool -14.29%
08:15AM  Benzinga's Daily Biotech Pulse: Insmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing Benzinga
May-22-18 06:00PM  Ardelyx Announces Pricing of Public Offering of Common Stock PR Newswire -19.47%
08:05AM  Benzinga's Daily Biotech Pulse: Melinta, Ardelyx Pull Back On Offerings, Insys Awaits FDA Verdict Benzinga
May-21-18 04:02PM  Ardelyx Raises $50 Million in Loan Agreement with Solar Capital and Bridge Bank PR Newswire
04:01PM  Ardelyx Announces Proposed Public Offering of Common Stock PR Newswire
May-08-18 05:56PM  Ardelyx: 1Q Earnings Snapshot Associated Press
04:05PM  Ardelyx Reports First Quarter 2018 Financial Results and Recent Business Highlights PR Newswire
Apr-05-18 08:15AM  Analysis: Positioning to Benefit within Euronet Worldwide, Innospec, Zosano Pharma, Ardelyx, Crown Castle International, and Aldeyra Therapeutics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Mar-19-18 06:30AM  Ardelyx and Knight Collaborate to Bring Tenapanor to Patients in Canada PR Newswire
Mar-14-18 04:34PM  Ardelyx posts 4Q profit Associated Press
04:05PM  Ardelyx Reports 2017 Financial Results and Appoints Industry Veteran, Jan Lundberg, Ph.D., to Board of Directors PR Newswire
Feb-26-18 08:20AM  Consolidated Research: 2018 Summary Expectations for Progress Software, Cracker Barrel Old Country Store, Natural Grocers by Vitamin Cottage, VBI Vaccines, Ardelyx, and CytomX Therapeutics Fundamental Analysis, Key Performance Indications GlobeNewswire
Feb-12-18 06:30AM  Ardelyx Announces Departure of Chief Scientific Officer PR Newswire
Feb-08-18 06:30AM  Ardelyx to Participate in Leerink Partners 7th Annual Global Healthcare Conference PR Newswire -6.82%
Feb-02-18 11:02AM  Best NasdaqGM Growth Stocks Simply Wall St. -8.57%
Jan-29-18 01:40PM  5 Great Breakout Stocks Offering Superlative Returns InvestorPlace
Jan-19-18 08:20AM  Zacks.com highlights: Sanchez Midstream Partners, Tecnoglass, Aeterna Zentaris, Ardelyx and Matrix Service Zacks
Jan-18-18 09:32AM  5 Great Breakout Stocks Offering Superlative Returns Zacks
Jan-04-18 05:03AM  Can The Uptrend Continue for Ardelyx (ARDX)? Zacks
Jan-03-18 07:58AM  Ardelyx Inc (NASDAQ:ARDX): Is It A Good Long Term Opportunity? Simply Wall St.
06:35AM  Ardelyx Announces Presentation at J.P. Morgan 36th Annual Healthcare Conference PR Newswire
06:30AM  Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C PR Newswire
Jan-01-18 11:02AM  January Growth Stock Opportunities Simply Wall St.
Dec-26-17 08:54AM  Why Ardelyx (ARDX) Could Beat Earnings Estimates Again Zacks
Dec-11-17 06:00AM  Ardelyx Announces License Agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China PR Newswire
Dec-01-17 09:33AM  Zacks.com featured highlights: Akari Therapeutics, Joint, Tailored Brands, Ardelyx and BioTime Zacks
Nov-30-17 08:20AM  5 Affordable Breakout Stocks Offering Excellent Returns Zacks
Nov-28-17 09:32AM  Ardelyx Jumps on License Deal; Otonomy Rises on Otividex News -- Biotech Movers TheStreet.com +8.40%
02:00AM  Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan PR Newswire
Nov-21-17 09:27AM  Cytokinetics Shares Plunge on Study Results for ALS Drug -- Biotech Movers TheStreet.com +12.50%
06:30AM  Ardelyx Announces Updated Development Path for its Cardiorenal Pipeline PR Newswire
Nov-07-17 06:45AM  Ardelyx reports 3Q loss Associated Press
06:30AM  Ardelyx Reports Third Quarter 2017 Operating Results and Clinical Progress PR Newswire
Oct-31-17 12:02PM  Growth Stocks Investors Love Simply Wall St. +5.94%
Oct-18-17 02:20PM  H.C. Wainwright Pounds the Table on Synergy Pharmaceuticals Inc (SGYP) SmarterAnalyst
Oct-16-17 08:01AM  Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling PR Newswire -12.03%
Oct-14-17 10:34AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Oct-13-17 08:00AM  Todays Research Reports on Stocks to Watch: Ampio Pharmaceuticals and Ardelyx Inc. ACCESSWIRE -6.73%
Oct-12-17 05:10PM  Why Ardelyx Inc Skyrocketed Higher Today Motley Fool +44.44%
04:31PM  Why Spartan Motors, Ardelyx, and Glu Mobile Jumped Today Motley Fool
10:30AM  Ardelyx IBS-C Candidate Succeeds in Pivotal Study, Stock Up Zacks
09:29AM  Ardelyx Soars on Positive Phase 3 Data -- Biotech Movers TheStreet.com
Oct-11-17 04:40PM  Ardelyx jumps more than 60% after positive study results MarketWatch
04:10PM  Ardelyx's irritable bowel syndrome drug succeeds in trial Reuters
04:02PM  Ardelyx's Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018 PR Newswire
Aug-13-17 06:16AM  Edited Transcript of ARDX earnings conference call or presentation 9-Aug-17 12:00pm GMT Thomson Reuters StreetEvents
Aug-09-17 09:45PM  Ardelyx reports 2Q loss Associated Press +8.05%
06:44AM  Ardelyx reports 2Q loss Associated Press
06:30AM  Ardelyx Focuses Resources on Late-Stage Programs and Reports Second Quarter 2017 Operational Results PR Newswire
05:10AM  Investor Network: Ardelyx, Inc. to Host Earnings Call ACCESSWIRE
Aug-02-17 06:30AM  Ardelyx Announces Date of Second Quarter Financial Results and Presentation at Wedbush PacGrow Healthcare Conference PR Newswire
Aug-01-17 09:40AM  LD Micro Index Reconstitution as of August 1, 2017 ACCESSWIRE
Jul-10-17 09:30AM  Zacks.com featured highlights: Ardelyx, Novavax, BioScrip, Layne Christensen and Resonant Zacks
Jul-07-17 08:41AM  5 Breakout Stocks Offering Phenomenal Returns Zacks +6.86%
May-29-17 01:32PM  With Ardelyx's Fall, Does Synergy Now Have a Clear Path to Victory? Motley Fool
May-15-17 04:59PM  What Do the Ardelyx Numbers Mean for the Company? GuruFocus.com
08:15AM  Blog Coverage: Ardelyx Reports Successful Trial Results for Treatment of Patients with Irritable Bowel Syndrome with Constipation Accesswire
May-12-17 06:30AM  Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C PR Newswire
May-05-17 06:41AM  Ardelyx reports 1Q loss Associated Press
06:30AM  Ardelyx Reports First Quarter 2017 Operating Results and Highlights Recent Progress PR Newswire
Apr-18-17 06:30AM  Ardelyx To Present at Upcoming Spring Medical Meetings PR Newswire
Mar-21-17 05:07PM  ARDELYX, INC. Files SEC form 8-K, Other Events
Ardelyx, Inc., a specialized biopharmaceutical company, develops and sells medicines for the treatment of cardio renal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rosenbaum David P.Chief Development OfficerJan 02Sale1.708011,36318,029Jan 04 07:13 PM
Rosenbaum David P.Chief Development OfficerJan 02Sale1.705,5859,503160,027Jan 04 07:13 PM
RAAB MICHAELPresident & CEOJan 02Sale1.7019,64433,418261,409Jan 04 07:11 PM
GRAMMER ELIZABETH AEVP, General CounselJan 02Sale1.704,9208,370129,284Jan 04 07:10 PM
Kaufmann MarkChief Financial OfficerJan 02Sale1.706,55611,154139,933Jan 04 07:11 PM
RAAB MICHAELPresident & CEONov 13Sale2.846,53918,571292,499Nov 15 05:41 PM
Kaufmann MarkChief Financial OfficerNov 13Sale2.846,53918,571146,489Nov 15 05:40 PM
Rosenbaum David P.Chief Development OfficerNov 13Sale2.845,57015,819165,612Nov 15 05:39 PM
GRAMMER ELIZABETH AEVP, General CounselNov 13Sale2.846,53918,571134,204Nov 15 06:07 PM
SANDELL SCOTT D10% OwnerNov 12Sale2.985921,7670Nov 13 04:55 PM
RINGOLD GORDONDirectorMay 30Buy4.0010,00040,00025,000Jun 01 06:21 PM